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Abstract 
Pregabalin is a psychoactive drug indicated in the treatment of epilepsy, neuropathic pain and 
generalized anxiety disorders. Pregabalin acts on different neurotransmission systems by 
inactivating the alpha2-delta subunit of voltage-gated calcium channels. In light of this 
pharmacological property, the hypothesis has been raised that pregabalin may regulate the 
mesolimbic dopamine pathway and thereby display a potential for misuse or abuse as recently 
observed in humans. Although some preclinical data support this possibility, the rewarding 
properties of gabapentinoid is still a matter for debate. The aim of this work was to evaluate 
the rewarding properties of pregabalin and to determine its putative mechanism of action in 
healthy mice. Pregabalin alone (60 mg/kg; s.c.) produced a rewarding effect in the conditioned 
place preference (CPP) test albeit to a lower extent than cocaine (30 mg/kg; s.c.). Interestingly, 
when assessing locomotor activity in the CPP, the PGB60 group, similarly to the cocaine 
group, showed an increased locomotor activity. In vivo single unit extracellular recording 
showed that pregabalin had mixed effects on dopamine (DA) neuronal activity in the ventral 
tegmental area since it decreased the activity of 50% of neurons and increased 28.5% of them. 
In contrast, cocaine decreased 75% of VTA DA neuronal activity whereas none of the neurons 
were activated. Intracerebal microdialysis was then conducted in awake freely mice to 
determine to what extent such electrophysiological parameters influence the extracellular DA 
concentrations ([DA]ext) in the Nucleus Accumbens. Although pregabalin failed to modify this 
parameter, cocaine produced a robust increase (800%) in [DA]ext. Collectively these 
electrophysiological and neurochemical experiments suggest that the rewarding properties of 
pregabalin result from a different mode of action than that observed with cocaine. Further 
experiments are warranted to determine whether such undesirable effects can be potentiated 
under pathological conditions such as neuropathic pain, mood disorders or addiction and to 
identify the key neurotransmitter system involved.  
Keywords: Rewarding properties, Pregabalin, Dopamine, VTA, nucleus accumbens 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
 
 
1. Introduction 
The neuroanatomical reward circuitry (Feltenstein et al., 2008; Volkow and Morales, 2015) 
involved in addiction underlies the integration of pleasurable stimuli induced by motivational 
behaviours found in substance use disorders and recruits the dopaminergic meso-cortico-
limbic neuronal system. Dopaminergic neurons from the Ventral Tegmental Area (VTA) have 
projections in several cerebral areas including the nucleus accumbens (NAc) (Marie and 
Noble, 2012). The release of dopamine (DA) in the NAc generates positive reinforcement 
under physiological condition, which motivates to seek behaviours sources of pleasure. Under 
the addictive state uncontrolled release of DA generates a behavioural response leading to 
the compulsive seeking of reward. Substances with an abuse/addiction potential activate the 
reward system and increase dopaminergic transmission in the NAc. For example, 
amphetamines increase DA release and cocaine inhibits its reuptake (Pettit and Justice, 1991). 
Other substances have indirect action, decreasing the inhibition of dopaminergic transmission 
physiologically induced in the VTA by GABAergic neurons. For example, the binding of opioids 
to µ opioid receptors expressed on GABAergic neurons located in the VTA blocks GABA-
induced tonic inhibition of DA neurons and leads to increased extracellular DA concentrations 
(Matsui et al., 2014).  
The pharmacological properties underlying the abuse/addiction potential of several 
psychoactive substances are currently not precisely established. It is notably the case for 
pregabalin (PGB). PGB is the active principle of a medical drug (Lyrica® and generic 
specialties) indicated for use in epilepsy and neuropathic pain, and since 2006 for the 
treatment of generalized anxious disorders. It is a gabapentinoid, i.e. a structural analogue of 
GABA presenting no effect on GABAergic transmission (Ben-Menachem, 2004). In contrast, 
PGB displays a high affinity toward voltage-gated calcium channel α2-1 subunits (Ki = 180 
nM) (Li et al., 2011). This subunit is expressed by muscular cells (skeletal, cardiac, smooth) 
and also found in the central and peripheral (dorsal root ganglion) nervous systems (Dolphin, 
2013). The cerebral regions expressing PGB binding sites are numerous and notably include: 
the cerebral cortex, the hippocampus, the amygdala, and the cerebellum (Bian et al., 2006). 
Voltage-gated calcium channels are inhibited by PGB, which prevents neuronal depolarization 
thereby decreasing the release of various neurotransmitters such as glutamate or substance 
P (Taylor et al., 2007).  
The eventuality of an abuse/addiction potential has been specifically examined in vitro and in 
vivo during the pharmaceutical development of PGB (Balster et al., 2013). In 2001, a 
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conditioned place preference (CPP) study, concluded that PGB did not have rewarding 
properties in the rat and decreased those of morphine (Andrews et al., 2001). Ten years later, 
a new study using the same test but a different protocol (route of administration) challenged 
these results (Rutten et al., 2011). In humans, the reported rate of euphoria among patients 
who participated in PGB clinical trials was 6-fold greater in those treated with PGB than in 
those treated with placebo (Zaccara et al., 2011). The first PGB-related abuse/addiction cases 
were reported shortly after PGB was marketed in European countries and in the USA (Olaizola 
et al., 2006; Yargic and Ozdemiroglu, 2011; Filipetto et al., 2010; Papazisis et al., 2013). 
Although inaugural addiction to PGB without history of substance abuse is described (Driot et 
al., 2016a), these cases most frequently occur in subjects of male gender and in a context of 
polydrug use or with a history of substance use disorders (Gahr et al., 2013; Schjerning et al., 
2016). Several PGB-related abuse/addiction alerts have been identified from national 
pharmacovigilance system databases (Schwan et al., 2010; Bossars et al., 2016). On the 
Internet, PGB is described by users who divert it for recreational purposes as « an ideal 
psychotropic drug » with anxiolytic effects mixed with euphoria (Schifano et al., 2011). In 
addition, the number of patients self-administering higher than recommended doses of PGB 
to achieve euphoric highs has increased, and the prevalence of gabapentinoid abuse has at 
least doubled among opioid abusers (Evoy et al., 2017). By contrast, another review of 
literature concluded that the rewarding properties of PGB, although higher than those of 
gabapentin, were low and occurred only in doses assumed to be supratherapeutic (Bonnet 
and Scherbaum, 2017).  
So, there are still questions on the mechanism underlying PGB’s abuse/addiction potential. In 
2003 already – i.e. at a time when PGB was in stage III clinical trials –, a review article on 
GABAergic drugs presented the potential wide therapeutic applications of PGB but noted the 
absence of available data on long-term use and thus, concluded with the need to evaluate 
tolerance, dependence and withdrawal or discontinuation reactions (Ashton and Young, 2003). 
On this background, the present study was aimed at comparing the effects of PGB and cocaine 
in healthy mice to gain insight into the mechanisms controlling the effects of this 
pharmacological agent observed in human. Assuming that PGB’s neuromodulatory effects on 
the meso-accumbens DA neuronal system could be at the origin of the related abuse/addiction, 
we combined behavioural, electrophysiological and neurochemical approaches to gain 
valuable insight into its pharmacological properties. 
2. Experimental procedures
2.1. Animals 
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 5 
Adult C57BL/6j male mice were purchased from Janvier Laboratories (Le Genest St. Isle, 
France). Animals were housed four to five per cage with a 12/12h day/night cycle (lights on at 
7:00 am) in temperature-controlled rooms (22° ± 2 °C). Food and water were available ad 
libitum. After arrival, animals were allowed to acclimatize for at least 2 weeks before testing 
during the light phase of the day-night cycle. All experiments were carried out in accordance 
with the European guidelines for the care of laboratory animals (European Communities 
Council Directive 86/609/ECC) and approved by the local Ethics Committee and the French 
Ministry of Education and Research (APAFIS#6659-2016090512114815 v3). 
2.2. Drugs  
All pharmacological drugs were dissolved in 0.9% saline and injected using the subcutaneous 
(s.c.) route which represents a rapid, inexpensive, and simple method of systemic substance 
administration with a good absorption rate (Kagan, 2014). For acute experiments, we tested 
pregabalin (PGB; Manchester Organics Ltd, UK) at the increasing doses of 10, 30 and 60 
mg/kg. The choice of these doses was based on previous observations that an oral 
administration of PGB (3-30 mg/kg) had no effect in the CPP test (Andrews et al., 2001). 
Cocaine (Sigma - Aldrich, Saint - Quentin Fallavier, France) was tested at the dose of 30 mg/kg 
and used herein as a positive control. For chronic experiments, repeated administrations of 
PGB (60 mg/kg) and cocaine (30 mg/kg) for 4 days were performed. Pharmacological controls 
for the electrophysiology experiments were conducted using apomorphine (0.5 – 1 mg/kg; s.c.) 
and haloperidol (5 mg/kg; s.c.), a D2 receptor agonist and antagonist; respectively (Sigma - 
Aldrich, Saint - Quentin Fallavier, France). For all administrations, the volume of injection was 
10ml/kg. 
2.3.1 Conditioned Place Preference 
CPP test was done in a custom-made plastic apparatus consisting of two equal size chambers 
(25 × 25 × 25 cm). A closed door separated these chambers during the conditioning days 
whereas the animals had free access to both compartments during the pre-conditioning and 
testing days. The two conditioning compartments had different visual and tactile cues. The first 
compartment contained a rough floor and checked walls (black and white) whereas the second 
compartment contained a smooth floor with grey plain walls. On the pre-test session, animals 
were given free access to the two chambers and allowed explore the apparatus for 10 min 
(familiarization). Animals were then placed a second time in the apparatus one hour later to 
freely explore for 20 minutes. During the latter session, video tracking (Ethovision Noldus, 
Wageningen, The Netherlands) allowed recording the time spent by the mice in each chamber 
and their locomotor activity.  Animals showing a preference (>65%) for any of the two 
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6 
conditioning compartments were discarded from the study (n=2). Drug injections were paired 
at random with a compartment (CS+ chamber), and saline was given in the other side (CS− 
chamber). The conditioning phase consisted in 4 consecutive training days with two daily 
training sessions lasting 20 min. Cocaine and PGB were given just prior to placing the animal 
in the CS+ chamber and saline prior to the CS− chamber (chambers and time of day were 
counterbalanced within groups). To prevent an association between injection and the time of 
day, drug injections were counterbalanced between morning and afternoon each day of 
conditioning period. Moreover, to obtain an effective association between substances tested 
and a single compartment, the two daily sessions were spaced by 5 hours. The day after the 
final training session, a 20-min test session consisted in giving mice free access to the 
apparatus in a drug-free state. Animals were initially placed in the compartment opposite to 
the one in which they started the pre-conditioning session. CPP score was expressed as the 
percentage of time spent in the CS+ compartment. 
2.3.2 Open field 
Mice were tested in an open field to assess locomotor activity 20 minutes after a single 
subcutaneous administration of saline, cocaine or PGB 60 mg/kg. The circular field dimensions 
were 40 x 30 cm. The tests were conducted in the morning, following habituation to the 
experimentation room (1 hour in the home cage). Mice were tracked for 20 minutes by video 
tracking (Ethovision Noldus, Wageningen, The Netherlands). Just after drug administration, 
each animal was placed in the center of the open field at the beginning of the test. The open 
field was cleaned with 30% ethanol between animals. Locomotor activity score was expressed 
as distance travelled (in cm). 
2.4. Study of dopaminergic system activity 
2.4.1 In vivo single-unit recordings 
Mice were anaesthetized with chloral hydrate and placed in a stereotaxic frame (David Kopf 
mouse adaptor) with the skull positioned horizontally. A glass micropipette (Stoelting, UK) filled 
with 2M NaCl was used for recordings. These micropipettes were previously stretched using 
a gravitational strainer (Narishige, Japan) in order to obtain a resistance between 5-8 M. 
They were then inserted into the ventral tegmental area (VTA) using the following coordinates 
(in mm from bregma according to the atlas of Paxinos & Franklin, 2001): AP: -3 to -3.3, L: ±0.3 
to 0.6 and V: 4.1 to 4.6 mm ventral to the brain surface. 
The extracellular potential was recorded with an amplifier and filter (300/0.5 Hz). Single-neuron 
spikes were collected on-line (CED 1401, SPIKE 2, Cambridge Electronic Design). Specific 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 7 
electrophysiological criteria were used to identify putative DA neurons. These included long-
duration (>2.0 ms) biphasic or triphasic action potential, with an initial phase exceeding >1.0 
ms in length, a low firing rate (<10 Hz), and a firing pattern that consisted of irregular single 
spike pattern with slow bursting activity (characterized by spike-amplitude decrement) 
according to Grace and Bunney, 1983. The mode of discharge was analyzed by spike interval 
burst analysis. The onset of a burst was defined as the occurrence of two spikes with an inter-
spike interval shorter than 0.08 s. The termination of bursts was defined as an inter-spike 
interval (ISI) of >0.16 s.  
 
For acute experiments, each recording lasted at least 20 minutes. After stabilization, the basal 
firing rate of VTA DA neurons was measured for 2 min. Saline or pharmacological agents were 
then injected subcutaneously and a period of at least 5 min was observed between each 
injection. Again, after stabilization the firing rate was measured in the last 2 min. This procedure 
allowed comparing the discharge frequency before and after the systemic administration of 
saline or the drugs and conduct pairwise comparison for each animal.  At the end of each 
recording, a pharmacological validation was realized using the D2 receptor agonist 
apomorphine, which was previously shown to reduce VTA DA neuronal activity (Oosterhof et 
al., 2014). The ability of the D2 receptor antagonist haloperidol to reverse the effects of 
apomorphine further confirmed the dopaminergic nature of the recorded neurons. Spike2 
software was used during the recording to measure the dopaminergic neurons firing rate 
(Hertz: number of AP/second), burst frequency and the action potential number into a burst.  
For chronic experiments, the basal firing rate of each putative VTA DA neurons encountered 
per tract was measured for 5 min in PGB or saline-injected mice. Three tracts per animals 
were conducted in order to determine the average of firing rate of all recorded neurons but 
also their mode of discharge (burst and spikes per burst).  
2.4.2 Intracerebral microdialysis in awake freely moving mice 
Extracellular levels of DA were measured in the nucleus accumbens (NAc) of awake, freely 
moving mice by microdialysis prior to and following drug administration. Samples collections 
were preceded by a surgical procedure during which the microdialysis probes were inserted 
into the brain area of interest. Mice were anaesthetized with chloral hydrate (400 mg/kg; i.p.) 
and implanted with probes in the NAc using the following coordinates (in mm from bregma: 
AP: +0.98, L: ±1.3, V: −5). Animals were then allowed to recover from the surgery overnight 
as previously described (Maskos et al., 2005; Barik et al., 2010). This short delay allows the 
optimization of samples collection by limiting the impairment of dialysis membrane and thereby 
avoids biased estimates of the neurotransmitter concentrations at the sampling site. Hence, 
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 8 
approximately 20 h after surgery the probes (without guide cannula) were continuously 
perfused with artificial cerebrospinal fluid (aCSF: NaCl 147 mmol/L, KCl 2.7 mmol/L, CaCl2 
1.26 mmol/L, MgCl2 1 mmol/L, NaH2PO4 2.0 mmol/L, NaHCO3 2.0 mmol/L; pH 7.4 ± 0.2) at a 
flow rate of 1.5 μL/min using a CMA/100 pump (Carnegie Medicin, Stockholm, Sweden). 
Before microdialysis sessions, all animals were carefully checked and if signs of pain were 
detected in the home cage, experiments were immediately stopped. Otherwise, two hours after 
the start of a continuous aCSF perfusion (stabilization period), four fractions were collected 
every 15 min into small Eppendorf tubes (Eppendorf, Le Pecq, France). These samples were 
used to measure the basal values of extracellular DA levels (mean ± SEM) calculated for each 
mouse prior to acute administration of vehicle, cocaine or PGB. Twelve subsequent 15-min 
samples were collected (t15- t120) and extracellular DA levels determined as percentage of 
baseline.  
Dialysate samples were analysed for DA by a high-performance liquid chromatography method 
(limit of sensitivity near 0.5 fmol/sample; signal-to-noise ratio = 2) using Chromeleon Lab 7.2 
software (Chromeleon Chomatography Data System. Thermo Fisher Scientific, USA).  
 
2.5. Data analysis  
Results were expressed as mean ± SEM. For electrophysiological and microdialysis (AUC) 
experiments, unpaired t-test was used to compare the firing parameters of VTA DA neurons 
between cocaine-injected mice and their controls. A one-way analysis of variance (ANOVA) 
for treatment factor was applied to compare these parameters between PGB-injected mice 
and their controls. For the analysis of the cocaine or PGB effects on DA extracellular levels 
(kinetics) and the CPP test, a two-way ANOVA with time and treatment factors was used. 
When a main effect of time or interaction time x treatment was significant, comparisons 
between treatments were analysed using a PLSD post-hoc test. Finally, for behaviour (CPP), 
the percentage of time spent in the CS+ compartment was analysed using a one sample t-test 
(comparison to the 50% chance value) to reveal a place preference/aversion. Prism7 software 
(Graphpad, San Diego, USA) was used for these statistical analyses and significance level 
was set at p<0.05. 
 
 
3. Results 
 
3.1. Behavioural tests 
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3.1.1 Conditioned Place Preference  
 
Mice were subjected to conditioned place preference, thus assessing the rewarding effect of 
cocaine and PGB. A significant preference was demonstrated by a percent of time spent in the 
conditioning compartment superior to 50% (chance level). After cocaine conditioning (30 
mg/kg; s.c.), the place preference for the drug-paired side was statistically significant (66.3 ± 
2 %; p = 0.001; fig. 1A). For PGB conditioning, only the dose of 60 mg/kg induced a significant 
preference for the drug paired side (55.4 ± 1.6 %; p = 0.006; fig. 1A). Moreover, a two-way 
ANOVA [treatment x conditioning] was carried out showing a significant effect of treatment 
factor (F(3,30)= 3.04, p<0.04), conditioning factor (F(1,30)= 36.3 : p<0.001) and treatment x 
interaction (F(3,30)=3.29; p=0.02). Post-hoc analyses revealed a significant increase of time 
spent in the drug-paired side after cocaine (p<0.001; fig. 1) and PGB 60 mg/kg (p<0.016; fig. 
1A) conditioning compared to the pre-conditioning session. 
Regarding animal’s activity during pre- and post-conditioning tests, a two-way ANOVA 
[treatment x conditioning] was carried out showing no significant effect of treatment factor 
(F(3,30)= 0.37, p>0.05) but a significant effect of conditioning factor (F(1,30)= 26.4 : p<0.001). 
Interestingly, Bonferroni post-hoc test revealed an increase in the distance travelled after four 
days of conditioning with both cocaine and PGB 60mg/kg (p<0.01 and p<0.001; fig. 1B). 
 
3.1.2 Locomotor activity 
We also monitored the total ambulatory distance travelled in an open field for 20 minutes 
following acute drug administration. One-way ANOVA revealed a significant effect of treatment 
factor (F(2,12)= 27.8 : p<0.001). We observed that cocaine produced psychostimulant effects 
(cocaine: 20165 ± 2595 vs. NaCl: 5685 ± 781 cm; p<0.001) whereas PGB 60 failed to do so 
(PGB60: 5436 ± 558 vs. NaCl: 5685 ± 781 cm; p=0.99).  
 
3.2. In vivo recordings of VTA DA neurons 
 
3.2.1 Saline (NaCl 0.9%) 
In order to verify the stability of VTA DA neuronal activity, we injected saline and recordings 
were continued over 15 min. As expected, the electrophysiological properties of VTA DA 
neurons were not altered in response to saline injection (fig. 2). 
 
3.2.2 Cocaine (30 mg/kg; s.c.). 
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Eight DA neurons were identified and recorded within the VTA. The acute administration of 
cocaine (30 mg/kg; s.c.) decreased the firing rate of 75% of dopaminergic neurons (n = 6) 
whereas it increased this parameter in one cell (12.5%) and had no effect on another one 
(12.5%). Among the 75% of VTA DA neurons whose discharge was reduced, the mean basal 
firing rate was 5.4 ± 0.5 Hz before drug injection and it was significantly reduced to 4.5 ± 0.3 
Hz (p = 0.02; figs. 3A-D). As depicted in fig. 3D, the addition of the D2 receptor agonist 
apomorphine, completely silenced VTA DA neuronal activity whereas this effect was reversed 
by the D2 receptor antagonist haloperidol thereby confirming the dopaminergic nature of the 
recorded neurons. The analysis of the mode of firing showed that the decrease in VTA DA 
neuronal activity was due to a decrease in the burst frequency (p = 0.03; fig. 3B) but not in the 
number of spikes per burst (p = 0.14; fig. 3D). 
 
3.2.3 Pregabalin (PGB: 10, 30 and 60 mg/kg; s.c.). 
 
Fourteen DA neurons were identified and recorded within the VTA. The acute administration 
of cumulative doses of PGB (10, 30 and 60 mg/kg; s.c.) produced mixed results. Although PGB 
10 and 30 mg/kg failed to modify VTA DA neuronal activity, the highest dose of PGB decreased 
the firing rate of 50% of VTA DA neurons (n=7), increased 28,5% of them (n=4) while 21,5% 
did not show any modification (n=3). 
Among the 50% of VTA DA neurons whose discharge was reduced, the mean basal firing rate 
was 5.9 ± 0.6 Hz before drug injection and this parameter was significantly reduced to 4.5 ± 
0.5 Hz (p = 0.01; figs. 4A-D). This decrease was not related to an attenuation of the burst 
frequency and the number of spikes per burst, (p>0.05; figs. 4B-C). Among PGB-excited VTA 
DA neurons, (p = 0,04; figs. 5A-D) the mean basal firing rate was 4.4 ± 0.7 before PGB and 
significantly increased to 5.4 ± 0.9 after drug administration. However, no differences were 
detected in the burst frequency and the number of spikes per burst (p > 0.05). 
 
3.3. Microdialysis 
 
3.3.1. Cocaine (30 mg/kg; s.c.). 
 
Two-way ANOVA [treatment x time] on the [DA]ext in the NAc indicated significant main effects 
of treatment factor (F(1,10)= 125 ; p<0.0001), time factor (F(8,80)=37 ; p<0.0001) and treatment x 
time interaction (F(8,80)=29.3 ; p<0.0001). Cocaine (30 mg/kg; s.c.) administration led to a 
significant increase in [DA]ext between t15 to t105 with a maximal effect observed 
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around 800% at t30 (fig. 6A). Statistical analysis on AUC (t0-t120min) values also indicated an 
overall significant increase in [DA]ext in the NAc in cocaine- relative to saline-injected mice (p< 
0.011; fig. 5B). 
3.3.2. Pregabalin (PGB: 10, 30 and 60 mg/kg; s.c.). 
Two-way ANOVA [treatment x time] on the [DA]ext in the NAc failed to unveil significant main 
effects of treatment factor (F(3,24)=1.964; p=0.14), time factor (F(8,192)=0.7769; p=0.62) and their 
interaction, (F(24,192)=0.9995 ; p=0,46). Similarly, statistical analysis on AUC (t0-t120min) values 
did not show any difference between treatments (F(3,21)=1.968 ; p=0.15 ; figs. 7A-B) thereby 
suggesting that PGB had no effect on DA tone in the NAc. 
3.4. Repeated administration of pregabalin 60 mg/kg 
To study the electrophysiological and neurochemical effects of PGB in the same conditions 
than those used for behavioural experiments, we evaluated the impact of this pharmacological 
agent after its repeated administration for 4 consecutive days (fig. 8A).  
Unlike acute administration, repeated injections of PGB (60 mg/kg; s.c.) did no longer inhibit 
the mean firing rate of dopaminergic neurons and consequently, the neuronal activity was 
similar between PGB and NaCl-injected animals (p = 0.65; fig. 8B). Similarly, burst frequency 
and the number of spikes per burst did not differ between groups (p = 0.3 and p = 0.3, 
respectively; figs. 8C-D).  
In microdialysis experiments, basal [DA]ext in the NAc in response to repeated administration 
of PGB did not reveal significant difference relative to saline (2.6 ± 0.4 vs. 2.6 ± 0.5 pg/15 uL; 
p=0.9). Two-way ANOVA [treatment x time] on the [DA]ext in the NAc failed to unveil significant 
main effects of treatment factor (F(1,13)= 0.0812, p = 0.78), time factor (F(8,104)= 1.808, p = 0.08) 
and their interaction, (F(8,104)= 0.5612, p = 0.8). Similarly, statistical analysis on AUC (t0-
t120min) values did not show any difference between saline and PGB 60 (p = 0.63; figs. 8E-
F). 
4. Discussion
Although many authors contributed to the understanding of the mechanisms by which 
psychoactive substances produce their potent rewarding effects, there is still some uncertainty 
concerning some of these pharmacological agents such as PGB. Convergent evidence 
implicates the meso-accumbens DA neuronal system as a key brain circuit involved in abuse 
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potential (Volkow and Morales, 2015). For example, in the operant drug self-administration 
paradigm, which shows high predictive validity assessing the rewarding properties in rodents 
and nonhuman primate, DA receptor agonists are known to be self-administered systemically 
as well as locally into the NAc (Yokel and Wise 1978; Woolverton et al. 1984; Carlezon et al. 
1995). On the contrary, DA receptor antagonists given in low doses decrease the motivation 
to carry out high work requirements to obtain an infusion of cocaine (Hubner and Moreton 
1991; Richardson et al. 1993). In agreement with the latter observations, lesions or inactivation 
of the mesolimbic DA system in the VTA (Roberts and Koob 1982; Shoaib et al. 1998) or the 
NAc (Roberts et al. 1977; Pettit et al. 1984; Shoaib et al. 1998) attenuate cocaine self-
administration in rats. More recently, the emergence of new technologies such as opto- and 
chemo-genetic tools has confirmed the key role of the meso-accumbens DA circuit in the 
rewarding effects of cocaine (Larson et al., 2015). Here, we used the conditioned place 
preference (CPP) test to compare the abuse potential of cocaine and PGB. The CPP test is a 
form of conditioning used to measure the motivational effects of drugs by quantifying the 
amount of time an animal spends in a compartment that has been associated with this stimulus. 
In particular, such paradigm has been successfully used to unveil the rewarding properties of 
dopaminergic compounds (Campbell et al., 2000; Childs et al., 2008). Our results indicate a 
marked place preference for the cocaine-paired side. The highest dose of PGB (i.e., 60 mg/kg) 
produced similar effects albeit less pronounced (66% vs 55%; respectively). Although the weak 
effect detected with PGB60 argues against a robust abuse liability in mice, it is noteworthy that 
a large proportion of mice displayed an increased percent of time spent in the drug-paired 
compartment after conditioning compared to baseline as observed with cocaine (Supp fig. 1). 
Interestingly, when assessing locomotor activity in the CPP in the absence of drug (pre-
conditioning vs post-conditioning sessions), we observed that the PGB60 group, similarly to 
the cocaine group, showed an increase in locomotion. This conditioned locomotion 
phenomenon has been associated with cue-induced craving (Hotsenpiller et al., 2002) further 
suggesting that PGB could display rewarding properties at the dose of 60 mg/kg. However, in 
contrast to cocaine, this drug-free conditioned effect is not accompanied by an acute hyper-
locomotor activity in response to PGB administration in the open-field. It is also plausible that 
the effects of PGB would have been more pronounced at higher doses or in experimental 
conditions displaying more salient and discriminant cues between CPP compartments.  
 To our knowledge, there are only few studies evaluating the rewarding properties of PGB and 
the results are mixed. In rats, an initial study reported that an oral administration of PGB (3-30 
mg/kg) had no effect in the CPP test (Andrews et al., 2001). However, these results have been 
challenged and a preference for the compartment paired with PGB was unveiled in response 
to its intraperitoneal administration at the doses of 3 and 10 mg/kg (Rutten et al., 2011). Our 
results obtained in mice with a higher dose of PGB agree with the latter study. The weak 
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percent of preference for the compartment that has been associated with PGB can be however 
puzzling and it is possible that the rewarding properties of PGB might be increased under 
specific experimental conditions. In keeping with this hypothesis, the rewarding effects of 
chronically administered PGB (3 mg/kg) were unveiled in a mouse model of neuropathic pain 
based on a partial sciatic nerve ligation (Bura et al., 2017). In a similar model, intraperitoneal 
injections of PGB (3 mg/kg) also induced place preference during 
the early stage of neuropathic pain (Asaoka et al., 2018). Finally, rewarding properties have 
been unveiled after carrageenan-induced mechanical hypersensitivity confirming the abuse 
potential of PGB (Rutten et al., 2011) although the possible antinociceptive effect of PGB in 
these models could also account for a place preference. It has also been speculated that PGB 
could modify the rewarding effects of other drugs of abuse. Different works described reduction 
in cocaine or alcohol self-administration in rats and humans treated with PGB (Stopponi et al., 
2012; de Guglielmo et al., 2013). In a recent study aimed at deciphering the interactions of 
PGB and morphine, it was demonstrated that pre-treatment with PGB suppressed morphine 
self-administration (Hasanein and Shakeri, 2014). Conversely, PGB was shown to contribute 
to oxycodone overdose deaths by reversing oxycodone-induced tolerance and significantly 
increasing respiratory depression in mice (Hill et al., 2018). Together, these data show that 
PGB has the capacity of counteracting the rewarding effects of opioids, but it also has a 
potentiating effect when given to mice with existing low opioid levels (Vashchinkina et al., 
2017). It is noteworthy that potential differences in the effects of PGB might exist between mice 
and humans. However, evidence demonstrates that the pharmacological targets of PGB are 
the same between both species and that its action in animals and humans is confined to 
neuronal synapses (Taylor et al., 2007, Li et al., 2011). 
Assuming the meso-accumbens DA neuronal circuit as an important component of rewarding 
properties, we then determined the effects of cocaine and PGB on this system using 
complementary electrophysiological and neurochemical approaches. We first investigated the 
effects of cocaine on the firing rate of VTA DA neurons. As previously shown (for review see 
White, 1990), cocaine reduced by ~20% the discharge of VTA DA neurons. Such effect results 
from the inhibition of DA reuptake. Indeed, this process is responsible for an accumulation of 
DA around dopaminergic neurons cell bodies, which in turn, activates an inhibitory feedback 
exerted by the somatodendritic D2 autoreceptors (White, 1990). The partial decrease in VTA 
DA neuronal activity observed here in response to cocaine can appear somewhat surprising 
notably owing to the high affinity of this drug for the dopamine transporter (DAT) (Uhl et al., 
2002). However, there is considerable amount of data demonstrating that the apparent lack of 
complete inhibition of DA neurons is a feature of this cell population. Indeed, the systemic 
administration or local application of selective D2 receptor agonists in the VTA produce a 
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partial decrease in the firing rate of DA neurons (Aghajanian et Bunney, 1977; White and 
Wang, 1984). It is also noteworthy that non-selective DA reuptake inhibitors such as 
GBR12909, SEP225289 or DOV216303 (Einhorn et al. 1988; Guiard et al., 2011) produce only 
weak inhibition of VTA DA neurons. Cocaine is a non-selective DAT inhibitor which also inhibits 
the reuptake transporters of serotonin (SERT) and norepinephrine (NET). The excitatory 
serotonergic and noradrenergic innervation of the VTA (Adell and Artigas, 2004; Esposito, 
2006) notably mediated by 5-HT2C (Pessia et al. 1994; Di Giovanni et al. 2000; Di Matteo et 
al. 2000;) and alpha1-adrenergic receptors (Grenhoff et al. 1995; Steffensen et al. 1998) have 
been proposed as key processes to limit the inhibitory effect of acutely administered cocaine 
on VTA DA neuronal activity. Using intracerebral microdialysis in awake freely moving mice, 
we showed that cocaine elicits a robust increase (800%) in extracellular DA levels in the NAc. 
Different microdialysis studies in the behaving rodents had previously yielded similar results 
demonstrating that the acute systemic administration of cocaine (Hernandez and Hoebel, 
1988; Bradberry and Roth, 1989; Kalivas and Duffy 1990; Kuczesnki et al. 1991; Pettit and 
Justice, 1991) but also other DAT inhibitors such as GBR12909 (Tsukada et al., 2000) or 
amphetamine (Di Ciano et al. 1995), increases DA levels in the NAc. Taken together our results 
strongly suggest that the rewarding properties of cocaine resulted from an increased 
extracellular DA levels in the NAc in response to the inactivation of the DAT. 
As regards PGB, our data revealed the existence of a subpopulation of VTA DA neurons that 
are inhibited by ~50% at the dose of 60 mg/kg. This electrophysiological response could 
suggest that PGB operates through the inactivation of the DAT as cocaine does. However, the 
fact that PGB did not increase extracellular DA levels in the NAc is not in favor of this 
hypothesis. Alternative mechanisms have to be foreseen. In particular, considering the 
excitatory serotonergic and noradrenergic innervation of the VTA, the possible interactions of 
PGB with both transmissions would deserve to be investigated in future research. Moreover, 
given the affinity and blocking activity of PGB on the α21 subunit of Ca2+ voltage-gated 
channels (Ben-Menachem, 2004), it is possible that the observed reduction in firing rate 
resulted from a decreased inward Ca2+ current in the VTA DA neurons thereby limiting cell 
depolarization but this hypothesis cannot explain the rewarding properties of PGB observed in 
the CPP test. Interestingly, our study also highlighted a subpopulation of VTA DA neurons 
(~30%) that were excited by PGB. Therefore, the rewarding properties of PGB could 
specifically rely on and be limited to these cells. One would expect that PGB inhibited Ca2+ 
voltage-gated channels expressed on GABAergic neurons thereby producing a disinhibitory 
action upon this subpopulation of VTA DA neurons. Another avenue that could be explored is 
the putative action of PGB on glia. Recent data demonstrate that microglia disrupts the 
mesolimbic system (Taylor et al., 2015). Assuming that PGB would modulate the activity on 
these non-neuronal cells as previously observed (Daneshdoust et al., 2017), it would be 
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tempting to examine this indirect relationship between PGB and VTA DA neurons. In a last 
series of experiments, we showed that repeated administration of PGB for 4 consecutive days 
at the dose of 60 mg/kg (chosen to mimic the CPP test conditions), did not influence the DA 
system. Previously, PGB (3 mg/kg) was shown to induce self-administration in the operant test 
after a 10-day period treatment (Bura et al., 2017) suggesting that a longer exposure to PGB 
may have been necessary to obtain a significant impact on DA levels in the NAc. However, 
the absence of elevated concentrations of DA in this brain region was not detrimental to obtain 
a behavioural response in the CPP in the present study. 
To further improve the understanding of the abuse/addiction potential of PGB, a 
complementary transversal approach should be implemented, in which animal models would 
be used to mimic different pathophysiological states found associated to PGB abuse in 
humans (Asomaning et al., 2016; Driot et al., 2016b; Schjerning et al., 2016; Evoy et al., 2017). 
Exposure to methadone, which constitutes an abuse/addiction marker, is an important factor 
of susceptibility identified in observational studies. So, to complement the results obtained in 
healthy mice, the mechanisms underlying PGB’s abuse/addiction potential should be 
investigated in animal models of dependence using experiments as in the present study. 
Indeed, the interaction between use of opioids and PGB is undeniable but complex. The 
analysis of postmortem toxicological data considered the increasing trend of PGB abuse and 
concluded on the mortality risk when PGB was combined with opioids, which were found 
concomitant in 91.4% of cases (Hakkinen et al., 2014).  
Conclusion 
A better understanding of the mechanisms involved in PGB’s abuse/addiction would help 
clinicians detect these disorders in their patients as well as manage them. A recent 
observational study found that 12.1% of opioid-dependent patients followed in an Addictology 
unit were also using PGB although they presented no medical indication to use it (Grosshans 
et al., 2013). Moreover, causes of sudden suspect deaths in individuals aged from 15 to 34 
years old were investigated in Finland (Launiainen et al., 2011). Overall, 10% of these deaths 
could be associated to PGB intake, 62% of which in a context of abuse/addiction. Surprisingly, 
this value was lower as opioids were concerned (fentanyl: 56%, tramadol: 55%, morphine: 
43%). In England in 2018, the study of non-medical use of prescription drugs identified PGB 
as one of the five psychoactive prescription drugs associated with fatal poisoning among 14 
studied (OR:2.60; 95% Confidence interval (CI): 1.61-4.20), after fentanyl (OR: 4.25; CI: 1.76-
10.23) and before oxycodone (OR: 2.51; 1.51-4.19), tramadol (OR: 2.23; CI: 1.49-3.35) and 
alprazolam (OR: 1.76; CI:1.18-2.60) (Haukka et al., 2018). It is thus essential to widespread 
the knowledge on this abuse/addiction potential among health professionals but also in the 
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general public, to raise awareness on the risks for PGB abusers as well as for patients being 
prescribed PGB, which are currently underestimated or even unknown. One consequence of 
this lack of consciousness is the underreporting of abuse cases to national or international 
pharmacovigilance systems resulting in the inability of these systems to identify PGB’s abuse 
potential (Bossard et al., 2016). 
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Figures legend 
Figure 1: Effect of Cocaine and Pregabalin on the development of conditioned place 
preference. Mean ± SEM of percentage of time spent in drug-paired side after cocaine 
30mg/kg (white; n=5), pregabalin (PGB) 10mg/kg (light grey; n=7), 30mg/kg (dark grey; n=7), 
60mg/kg (black; n=14). D0 represents results obtained during the pre-conditioning (dot pattern) 
and D5 represents results obtained after conditioning for the different groups (unified plain 
colors) (A). $ p <0.05 and $ p <0.01: significantly different from the chance level set at 50%. ** 
p <0.01 and *** p <0.001: significantly different from the percentage of time spent in the 
compartment during the pre-conditioning session. As mentioned in the methods, three mice 
were discarded owing to their spontaneous preference (>65%) for one compartment before 
conditioning. Mean ± SEM of distance travelled (in cm) in the absence of drugs in the 
conditioned place preference apparatus before (D0) and after (D5) conditioning (B). ** p <0.01 
and *** p <0.001: significantly different from the distance travelled in the arena during the pre-
conditioning session (D0). 
Figure 2. Lack of inhibition of the VTA dopaminergic neurons firing rate in response to 
an acute administration of saline. Mean ± SEM of firing rate (Hz) (A), burst frequency (Hz) 
(B) and number of spikes per burst (C) before (white) and after saline (NaCl 0,9%; s.c.) 
injection (black) (n=6). (D) Examples of integrated firing rate histograms of a VTA dopaminergic 
neuron showing its stability over time and average extracellular waveform of DA neuron. AP 
widths were measured from the start of the action potential to the negative trough (top) and 
used as a criterion to select presumed DA neurons. 
Figure 3. Inhibition of the VTA dopaminergic neurons firing rate in response to an acute 
administration of cocaine. Mean ± SEM of firing rate (Hz) (A), burst frequency (Hz) (B) and 
number of spikes per burst (C) before (white) and after cocaine (30mg/kg; s.c.) injection (black) 
(n=6). *p<0,05 and **p<0.01: significantly different from baseline. (D) Example of integrated 
firing rate histograms of a VTA dopaminergic neuron showing the responsiveness to injection 
of cocaine followed by apomorphine (1mg/kg; s.c.), a D2 receptor agonist and haloperidol 
(5mg/kg; s.c.), a D2 receptor antagonist. Apomorphine injection lead to a full inhibition of the 
firing rate while haloperidol completely reversed this electrophysiological response. Typical 
example of average extracellular waveform of DA neuron. AP widths were measured from the 
start of the action potential to the negative trough (top) and used as a criterion to select 
presumed DA neurons. 
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Figure 4: Inhibition of VTA dopaminergic neurons firing rate in response to an acute 
administration of pregabalin. Mean ± SEM of firing rate (Hz) (A), burst frequency (Hz) (B) 
and number of spikes per burst (C) before (white) and after acute repeated administration of 
pregabalin (PGB) at the doses of 10, 20 and 30 mg/kg; s.c. (grey/black) (n=7). This sequence 
of administration corresponds to cumulative doses of 10, 30 and 60 mg/kg of PGB. *p<0.05: 
significantly different from baseline. D- Examples of integrated firing rate histograms of a VTA 
dopaminergic neuron showing the responsiveness to injection of cumulative doses of PGB 
followed by an injection of apomorphine (0,5mg/kg; s.c.) and average extracellular waveform 
of DA neuron. AP widths were measured from the start of the action potential to the negative 
trough (top) and used as a criterion to select presumed DA neurons. 
Figure 5: Excitation of VTA dopaminergic neurons firing rate in response to an acute 
administration of pregabalin. Mean ± SEM of firing rate (Hz) (A), burst frequency (Hz) (B) 
and number of spikes per burst (C) before (white) and after acute repeated administration of 
pregabalin (PGB) at the doses of 10, 20 and 30 mg/kg; s.c. (grey/black) (n=4). This sequence 
of administration corresponds to cumulative doses of 10, 30 and 60 mg/kg of PGB. *p<0.05: 
significantly different from baseline. D- Examples of integrated firing rate histograms of a VTA 
dopaminergic neuron showing the responsiveness to injection of cumulative doses of PGB and 
and average extracellular waveform of DA neuron. AP widths were measured from the start of 
the action potential to the negative trough (top) and used as a criterion to select presumed DA 
neurons. 
Figure 6: Effects of an acute injection of cocaine on extracellular DA concentration in 
the Nucleus Accumbens.  (A) Mean ± SEM of extracellular DA levels expressed as % of 
baseline in saline- (NaCl; s.c.; n=8) (white) or cocaine-injected mice (30mg/kg; s.c.; n=8). The 
arrow indicates the time at which mice were injected. As expected, before saline or cocaine 
injection the mean basal levels of [DA]ext were not significantly different between groups (2,6 
± 0,4 vs. 3,1 ± 0,8 pg/15µL respectively; p>0.05). *p < 0.05, **p < 0.01, ***p < 0.001: 
significantly different from saline-injected mice at the corresponding time.  (B) Mean ± SEM of 
Area Under the Curve values following the administration of saline (NaCl) or cocaine in percent 
of baseline.  **p < 0.01: significantly different from saline-injected mice.  
Figure 7: Effects of an acute injection of pregabalin on extracellular DA concentration 
in the Nucleus Accumbens.  (A) Mean ± SEM of extracellular DA levels expressed as % of 
baseline in saline- (NaCl; s.c.; n=8) (white), PGB 10-(n=4; light grey ), pregabalin PGB 30- 
(n=8; dark grey ) and PGB 60 mg/kg- (n=8; ●). The arrow indicates the time at which mice 
were injected. As expected, the mean basal levels of [DA]ext was not significantly different 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
25 
between groups (2.6 ± 0.4; 2.9 ± 0.4; 2.0 ± 0.5 et 2.6 ± 0.4 pg/15µL; respectively). (B) Mean ± 
SEM of Area Under the Curve values following the administration of saline (NaCl) or PGB in 
percent of baseline.  
Figure 8: Effect of repeated administration of pregabalin on dopaminergic activity 
system. (A) Experimental protocol. Mice received a daily injection of PGB (60 mg/kg; s.c.) or 
NaCl (0.9%) for 4 days. Electrophysiological experiments were conducted on day 4 (D4) 30 
min after the last injection of PGB. Microdialysis experiments were also conducted on D4 and 
the last injection of PGB was realized during the samples collection. Mean ± SEM of firing rate 
(Hz)(B), burst frequency (Hz)(C) and number of spikes per burst (D) after repeated 
administration of saline (n= 51; white) or pregabalin 60mg/kg, s.c. (n=17; black). (E) Mean ± 
SEM of extracellular DA levels expressed as % of baseline in saline (NaCl; s.c.; n=8) (white) 
or PGB-injected mice (60mg/kg; s.c.; n=7). The arrow indicates the time at which mice were 
injected. As expected, before saline or cocaine injection the mean basal levels of [DA]ext were 
not significantly different between groups (2,6 ± 0,4 vs. 2.6 ± 0,5 pg/15µL respectively). (F) 
Mean ± SEM of Area Under the Curve values following the administration of saline (NaCl) or 
pregabalin (PGB) in percent of baseline. 
Supplemental Figure 1: Individual distribution of the percent of time spent in the drug-paired 
compartment before (D0) and after (D5) conditioning in response to cocaine (30 mg/kg; s.c.) 
(A) or pregabalin (PGB 60 mg/kg; s.c.).
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